Having trouble accessing articles? Reset your cache.

Meridia sibutramine: Phase III data

The double-blind, U.S. Phase III SCOUT trial in 10,744 overweight or obese patients >=55 years old with pre-existing cardiovascular disease and/or Type II diabetes showed that Meridia led to

Read the full 293 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE